According to a recent LinkedIn post from Circulate, the company’s clinical trial was referenced in a recent episode of the Huberman Lab Podcast focused on restoring youthfulness and vitality in aging. The post highlights that the episode featured Dr. Tony Wyss-Coray, described as a leading researcher in parabiosis and circulating factors in aging.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The post suggests that Circulate views this mention as evidence that systemic drivers of aging are gaining broader visibility in the longevity community. It notes what it describes as growing scientific convergence among leading labs, including researchers such as Wyss-Coray, Eric Verdin, and Matt Kaeberlein, around the idea that aging is influenced in part by circulating signals in the blood.
As interpreted from the post, Circulate positions plasma replacement or removal therapies as among the more plausible translational approaches for studying and potentially influencing these signals. For investors, the visibility on a high-traffic science podcast may modestly enhance Circulate’s profile in the longevity and healthspan sector, potentially supporting future fundraising, partnerships, or clinical collaboration opportunities.
The post also underscores that these therapeutic concepts continue to appear in broader longevity discussions as the underlying science advances. If this scientific and public interest trend continues, companies like Circulate that are developing plasma-based interventions could benefit from increased attention to aging-related therapeutics, though clinical validation, regulatory pathways, and payer adoption remain key determinants of long-term financial impact.